• Change in proliferation after statin exposure, as measured by Ki-67 level [ Designated as safety issue: No ]
  

• Blood and serum markers, including C-reactive protein, cleaved caspase 3, HER2, CD68, macrophages and immunoregulatory CD25 T cells, estrogen and progesterone receptors, mRNA, low-density lipoprotein, and cholesterol [ Designated as safety issue: No ]
  
• Presence of comedo necrosis [ Designated as safety issue: No ]
  
• Safety [ Designated as safety issue: Yes ]
  

OBJECTIVES:

Primary

• Determine differences between measures of cell proliferation (Ki-67) in women with ductal carcinoma in situ (DCIS) or stage I breast cancer receiving neoadjuvant fluvastatin sodium.

Secondary

• Determine whether statin use differentially affects specific types of DCIS/early-stage breast cancer (comedo, estrogen receptor [ER]-positive, ER-negative).
• Compare differences between tissue staining of CD68, circulating macrophages, and regulatory T cells in these patients.
• Assess the feasibility of using inherent susceptibility (mRNA polymerase chain reaction testing) to predict response to statins in these patients.

OUTLINE: This is a randomized, controlled, single-blind, multicenter, pilot study. Patients are randomized to 1 of 2 treatment arms (arms I or II). Patients accrued as control participants are assigned to arm III.

• Arm I: Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
• Arm II: Patients receive oral fluvastatin sodium as in arm I at a higher dose.
• Arm III (control): Patients do not receive fluvastatin sodium. All patients then undergo definitive surgery.

Patients in arms I and II undergo blood collection at baseline and at the time of surgery for biomarker analysis. Patients in arm III undergo blood collection at baseline and then approximately 1 month later. Tissue is collected from patients in all arms at the time of surgery. Blood and tissue samples are examined for biological markers, including Ki-67, C-reactive protein, cleaved caspase 3, HER2, CD68 gene, and estrogen and progesterone receptors by immunohistochemistry. Markers of inflammation (e.g., comedo necrosis macrophages and CD25-positive T cells), low-density lipoprotein, and cholesterol are also analyzed. Serum mRNA is measured by polymerase chain reaction.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

• Histologically confirmed ductal carcinoma in situ (DCIS) or stage I breast cancer by stereotactic core or incisional biopsy

• Planning to undergo surgery in 3-6 weeks

  • Patients undergoing re-excision due to evidence of tumor present at surgical margins are eligible
• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Female
• Menopausal status not specified
• ALT and AST ≤ 10% above upper limit of normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to tolerate statins
• Willing to undergo 2 blood draws (separated by approximately 3-4 weeks) during study participation (control arm)

PRIOR CONCURRENT THERAPY:

• No other concurrent statins
• No concurrent chemotherapy

• No concurrent administration of any of the following:

  • Niacin
  • Propranolol
  • Cholestyramine
  • Cyclosporine
  • Digoxin
  • Erythromycin
  • Itraconazole
  • Gemfibrozil
  • Phenytoin
  • Diclofenac
  • Tolbutamide
  • Glyburide
  • Losartan
  • Cimetidine
  • Ranitidine
  • Omeprazole
  • Rifampin
  • Warfarin
• No initiation of new hormonal therapy during study participation
• Concurrent participation in other clinical trials (e.g., for DCIS or prevention) is allowed